<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00532298</url>
  </required_header>
  <id_info>
    <org_study_id>110620</org_study_id>
    <nct_id>NCT00532298</nct_id>
  </id_info>
  <brief_title>Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over</brief_title>
  <official_title>Non-Inferiority of GlaxoSmithKline Biologicals' Influenza Vaccine (GSK576389A) 1 Container Over 2 Container Presentation in Adults Aged 65 Years and Over</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This observer blind study is designed to compare the immune response of GSK Biologicals'
      influenza vaccine GSK576389A when administered using various presentations in adults aged 65
      years and older. The Protocol Posting has been updated in order to comply with the FDA
      Amendment Act, Sep 2007.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study contains 6 parallel groups, stratified by two age groups: 65-74 years and ≥ 75
      years and by two influenza vaccination histories: no influenza vaccination in the last 3
      seasons and at least one influenza vaccination in the last 3 seasons.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haemagglutination Inhibition (HI) Antibody Titers for the H1N1 Vaccine Strain</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs). The H1N1 vaccine strains included A/New Caledonia and A/Solomon Islands antigens. A/New Caledonia vaccine strain was administered to both groups receiving the adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season. A/Solomon Islands vaccine strain was administered to both groups receiving the adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Titers Against Each of the Three Vaccine Strains for the Two Season Formulations</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>Antibody titers were expressed as GMTs. The vaccine strains included A/New Caledonia or A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. A/New Caledonia vaccine strain was administered to all groups receiving the Northern Hemisphere 2006/2007 influenza season vaccine formulations. A/Solomon Islands vaccine strain was administered to all groups receiving the Northern Hemisphere 2007/2008 influenza season vaccine formulations. A/Wisconsin and B/Malaysia vaccine strains were administered to all groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroconverted for HI Antibodies Against Each of the Three Vaccine Strains for the Two Season Formulations</measure>
    <time_frame>At Day 21</time_frame>
    <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/New Caledonia (for all groups receiving vaccine formulations for the Northern Hemisphere [NH] 2006/2007 influenza season) or A/Solomon Islands (for all groups receiving vaccine formulations for the NH 2007/2008 influenza season), A/Wisconsin and B/Malaysia antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Seroconversion Factors</measure>
    <time_frame>At Day 21</time_frame>
    <description>Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/New Caledonia (for all groups receiving vaccine formulations for the Northern Hemisphere [NH] 2006/2007 influenza season) or A/Solomon Islands (for all groups receiving vaccine formulations for the NH 2007/2008 influenza season), A/Wisconsin and B/Malaysia antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroprotected for HI Antibodies Against Each of the Three Vaccine Strains for the Two Season Formulations</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included A/New Caledonia (for all groups receiving vaccine formulations for the Northern Hemisphere [NH] 2006/2007 influenza season) or A/Solomon Islands (for all groups receiving vaccine formulations for the NH 2007/2008 influenza season), A/Wisconsin and B/Malaysia antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</measure>
    <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
    <description>Grade 3 ecchymosis, redness and swelling was greater than 100 millimeter (mm) i.e. &gt;100mm and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade. Any for ecchymosis, redness and swelling was &gt;20mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited Local AEs</measure>
    <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
    <description>Duration was defined as number of days with any grade of local symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</measure>
    <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
    <description>Any temperature was defined as oral temperature greater than or equal to 38.0 degree centigrade i.e ≥38.0°C, grade 3 temperature was oral temperature ≥39.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a general symptom that prevented normal activity. Related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited General AEs</measure>
    <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
    <description>Duration was defined as number of days with any grade of general symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</measure>
    <time_frame>During a 21-day follow-up period (Day 0-20) after vaccination</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Medically Significant Conditions (MSCs)</measure>
    <time_frame>During a 21-day follow-up period (Day 0-20) after vaccination</time_frame>
    <description>MSCs were defined as an AEs with a medically-attended visit (MAE) i.e. prompting emergency room (ER) visits, hospitalizations or physician visits and that were not routine visits for physical examination or vaccination. Any MSC was defined as at least one MSC experienced. Grade 3 was a MSC that prevented normal activities and related was defined as a MSC assessed by the investigator to be causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</measure>
    <time_frame>During a 21-day follow-up period (Day 0-20) after vaccination</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1596</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GSK576389A- 2006/2007 Season - 1 container Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK576389A - 2006/2007 Season - 2 containers Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix 2006/2007 Season Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK576389A - 2007/2008 Season - 1 container Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK576389A - 2007/2008 Season - 2 containers Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix 2007/2008 Season Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season]</intervention_name>
    <description>Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
    <arm_group_label>GSK576389A- 2006/2007 Season - 1 container Group</arm_group_label>
    <arm_group_label>GSK576389A - 2006/2007 Season - 2 containers Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season]</intervention_name>
    <description>Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
    <arm_group_label>GSK576389A - 2007/2008 Season - 1 container Group</arm_group_label>
    <arm_group_label>GSK576389A - 2007/2008 Season - 2 containers Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix [NH 2006/07 season]</intervention_name>
    <description>Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
    <arm_group_label>Fluarix 2006/2007 Season Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix [NH 2007/08 season]</intervention_name>
    <description>Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
    <arm_group_label>Fluarix 2007/2008 Season Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol should be enrolled in the study.

          -  A male or female aged 65 years or older at the time of the vaccination.

          -  Written informed consent obtained from the subject.

          -  Free of an acute aggravation of the health status as established by clinical
             evaluation before entering into the study.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days prior to vaccination, or planned use during the study
             period.

          -  Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or
             4 weeks (for live vaccines) prior to enrolment in this study. Planned administration
             of a vaccine not foreseen by the study protocol up to Visit 2 after vaccination.

          -  Planned administration of an influenza vaccine other than the study vaccines during
             the entire study period.

          -  Vaccination against influenza since January 2007 (including the Northern Hemisphere NH
             2006/2007 or NH 2007/08 influenza vaccine).

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the administration of the study
             vaccine.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination (no laboratory testing required).

          -  History of hypersensivity to a previous dose of influenza vaccine.

          -  History of allergy or reactions likely to be exacerbated by any component of the
             vaccine(s)

          -  Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional
             abnormality, as determined by clinical evaluation or pre-existing laboratory screening
             tests.

          -  Acute disease at the time of enrolment.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first administration of the study vaccine or planned administration
             during the study.

          -  Any medical conditions in which intramuscular injections are contraindicated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Soeborg</city>
        <zip>2860</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tartu</city>
        <zip>50417</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bergen</city>
        <zip>5094</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elverum</city>
        <zip>2408</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stavanger</city>
        <zip>4010</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2007</study_first_submitted>
  <study_first_submitted_qc>September 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2007</study_first_posted>
  <results_first_submitted>April 23, 2012</results_first_submitted>
  <results_first_submitted_qc>April 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 22, 2012</results_first_posted>
  <disposition_first_submitted>May 20, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 28, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 30, 2009</disposition_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fluarix</keyword>
  <keyword>Influenza Infection</keyword>
  <keyword>GSK Biologicals' influenza vaccine GSK576389A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>110620</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110620</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110620</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110620</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110620</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110620</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110620</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two subjects enrolled in this study were not vaccinated and as such not accounted for under Started.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK576389A- 2006/2007 Season - 1 Container Group</title>
          <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.</description>
        </group>
        <group group_id="P2">
          <title>GSK576389A - 2006/2007 Season - 2 Containers Group</title>
          <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.</description>
        </group>
        <group group_id="P3">
          <title>Fluarix 2006/2007 Season Group</title>
          <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
        </group>
        <group group_id="P4">
          <title>GSK576389A - 2007/2008 Season - 1 Container Group</title>
          <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.</description>
        </group>
        <group group_id="P5">
          <title>GSK576389A - 2007/2008 Season - 2 Containers Group</title>
          <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.</description>
        </group>
        <group group_id="P6">
          <title>Fluarix 2007/2008 Season Group</title>
          <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="269"/>
                <participants group_id="P2" count="266"/>
                <participants group_id="P3" count="264"/>
                <participants group_id="P4" count="264"/>
                <participants group_id="P5" count="268"/>
                <participants group_id="P6" count="263"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="267"/>
                <participants group_id="P2" count="265"/>
                <participants group_id="P3" count="263"/>
                <participants group_id="P4" count="264"/>
                <participants group_id="P5" count="267"/>
                <participants group_id="P6" count="261"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK576389A- 2006/2007 Season - 1 Container Group</title>
          <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.</description>
        </group>
        <group group_id="B2">
          <title>GSK576389A - 2006/2007 Season - 2 Containers Group</title>
          <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.</description>
        </group>
        <group group_id="B3">
          <title>Fluarix 2006/2007 Season Group</title>
          <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
        </group>
        <group group_id="B4">
          <title>GSK576389A - 2007/2008 Season - 1 Container Group</title>
          <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.</description>
        </group>
        <group group_id="B5">
          <title>GSK576389A - 2007/2008 Season - 2 Containers Group</title>
          <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.</description>
        </group>
        <group group_id="B6">
          <title>Fluarix 2007/2008 Season Group</title>
          <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="269"/>
            <count group_id="B2" value="266"/>
            <count group_id="B3" value="264"/>
            <count group_id="B4" value="264"/>
            <count group_id="B5" value="268"/>
            <count group_id="B6" value="263"/>
            <count group_id="B7" value="1594"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.2" spread="5.56"/>
                    <measurement group_id="B2" value="73.0" spread="5.16"/>
                    <measurement group_id="B3" value="72.8" spread="5.06"/>
                    <measurement group_id="B4" value="73.3" spread="5.86"/>
                    <measurement group_id="B5" value="73.2" spread="5.72"/>
                    <measurement group_id="B6" value="73.0" spread="5.20"/>
                    <measurement group_id="B7" value="73.08" spread="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="150"/>
                    <measurement group_id="B4" value="145"/>
                    <measurement group_id="B5" value="152"/>
                    <measurement group_id="B6" value="153"/>
                    <measurement group_id="B7" value="900"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="119"/>
                    <measurement group_id="B5" value="116"/>
                    <measurement group_id="B6" value="110"/>
                    <measurement group_id="B7" value="694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Haemagglutination Inhibition (HI) Antibody Titers for the H1N1 Vaccine Strain</title>
        <description>Antibody titers were expressed as Geometric mean titers (GMTs). The H1N1 vaccine strains included A/New Caledonia and A/Solomon Islands antigens. A/New Caledonia vaccine strain was administered to both groups receiving the adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season. A/Solomon Islands vaccine strain was administered to both groups receiving the adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity were available. This primary outcome was assessed only on those groups receiving any of the GSK Bio's influenza vaccine GSK576389A formulations.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK576389A- 2006/2007 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O2">
            <title>GSK576389A - 2006/2007 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 2006/2007 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
          </group>
          <group group_id="O4">
            <title>GSK576389A - 2007/2008 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O5">
            <title>GSK576389A - 2007/2008 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix 2007/2008 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
          </group>
        </group_list>
        <measure>
          <title>Haemagglutination Inhibition (HI) Antibody Titers for the H1N1 Vaccine Strain</title>
          <description>Antibody titers were expressed as Geometric mean titers (GMTs). The H1N1 vaccine strains included A/New Caledonia and A/Solomon Islands antigens. A/New Caledonia vaccine strain was administered to both groups receiving the adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season. A/Solomon Islands vaccine strain was administered to both groups receiving the adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season.</description>
          <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity were available. This primary outcome was assessed only on those groups receiving any of the GSK Bio's influenza vaccine GSK576389A formulations.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="258"/>
                <count group_id="O5" value="263"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia at Day 0 (N=259;259;0;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9" lower_limit="33.1" upper_limit="43.3"/>
                    <measurement group_id="O2" value="40.1" lower_limit="34.7" upper_limit="46.4"/>
                    <measurement group_id="O4" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                    <measurement group_id="O5" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia at Day 21 (N=259;259;0;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.8" lower_limit="117.0" upper_limit="146.3"/>
                    <measurement group_id="O2" value="138.5" lower_limit="123.2" upper_limit="155.8"/>
                    <measurement group_id="O4" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                    <measurement group_id="O5" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands at Day 0 (N=0;0;0;258;263;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O2" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O4" value="9.4" lower_limit="8.4" upper_limit="10.5"/>
                    <measurement group_id="O5" value="9.0" lower_limit="8.1" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands at Day 21 (N=0;0;0;258;263;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O2" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O4" value="82.0" lower_limit="70.9" upper_limit="94.8"/>
                    <measurement group_id="O5" value="88.6" lower_limit="76.4" upper_limit="102.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Titers Against Each of the Three Vaccine Strains for the Two Season Formulations</title>
        <description>Antibody titers were expressed as GMTs. The vaccine strains included A/New Caledonia or A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. A/New Caledonia vaccine strain was administered to all groups receiving the Northern Hemisphere 2006/2007 influenza season vaccine formulations. A/Solomon Islands vaccine strain was administered to all groups receiving the Northern Hemisphere 2007/2008 influenza season vaccine formulations. A/Wisconsin and B/Malaysia vaccine strains were administered to all groups.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK576389A- 2006/2007 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O2">
            <title>GSK576389A - 2006/2007 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 2006/2007 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
          </group>
          <group group_id="O4">
            <title>GSK576389A - 2007/2008 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O5">
            <title>GSK576389A - 2007/2008 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix 2007/2008 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody Titers Against Each of the Three Vaccine Strains for the Two Season Formulations</title>
          <description>Antibody titers were expressed as GMTs. The vaccine strains included A/New Caledonia or A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. A/New Caledonia vaccine strain was administered to all groups receiving the Northern Hemisphere 2006/2007 influenza season vaccine formulations. A/Solomon Islands vaccine strain was administered to all groups receiving the Northern Hemisphere 2007/2008 influenza season vaccine formulations. A/Wisconsin and B/Malaysia vaccine strains were administered to all groups.</description>
          <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity were available.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="255"/>
                <count group_id="O4" value="258"/>
                <count group_id="O5" value="263"/>
                <count group_id="O6" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia at Day 0 (N=259;259;255;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9" lower_limit="33.1" upper_limit="43.3"/>
                    <measurement group_id="O2" value="40.1" lower_limit="34.7" upper_limit="46.4"/>
                    <measurement group_id="O3" value="35.3" lower_limit="30.6" upper_limit="40.7"/>
                    <measurement group_id="O4" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                    <measurement group_id="O5" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                    <measurement group_id="O6" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia at Day 21 (N=259;259;255;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.8" lower_limit="117.0" upper_limit="146.3"/>
                    <measurement group_id="O2" value="138.5" lower_limit="123.2" upper_limit="155.8"/>
                    <measurement group_id="O3" value="114.7" lower_limit="102.0" upper_limit="129.0"/>
                    <measurement group_id="O4" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                    <measurement group_id="O5" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                    <measurement group_id="O6" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands at Day 0 (N=0;0;0;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O2" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O3" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O4" value="9.4" lower_limit="8.4" upper_limit="10.5"/>
                    <measurement group_id="O5" value="9.0" lower_limit="8.1" upper_limit="9.9"/>
                    <measurement group_id="O6" value="8.5" lower_limit="7.7" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands at Day 21 (N=0;0;0;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O2" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O3" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O4" value="82.0" lower_limit="70.9" upper_limit="94.8"/>
                    <measurement group_id="O5" value="88.6" lower_limit="76.4" upper_limit="102.7"/>
                    <measurement group_id="O6" value="61.0" lower_limit="52.1" upper_limit="71.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin at Day 0 (N=259;259;255;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" lower_limit="39.9" upper_limit="57.0"/>
                    <measurement group_id="O2" value="52.8" lower_limit="44.1" upper_limit="63.2"/>
                    <measurement group_id="O3" value="53.3" lower_limit="44.2" upper_limit="64.2"/>
                    <measurement group_id="O4" value="56.7" lower_limit="47.7" upper_limit="67.5"/>
                    <measurement group_id="O5" value="52.8" lower_limit="44.3" upper_limit="62.9"/>
                    <measurement group_id="O6" value="42.8" lower_limit="35.8" upper_limit="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin at Day 21 (N=259;259;255;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379.7" lower_limit="328.5" upper_limit="439.0"/>
                    <measurement group_id="O2" value="409.9" lower_limit="360.3" upper_limit="466.2"/>
                    <measurement group_id="O3" value="275.5" lower_limit="241.6" upper_limit="314.3"/>
                    <measurement group_id="O4" value="399.9" lower_limit="351.4" upper_limit="455.1"/>
                    <measurement group_id="O5" value="367.4" lower_limit="322.9" upper_limit="418.2"/>
                    <measurement group_id="O6" value="178.9" lower_limit="153.8" upper_limit="208.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia at Day 0 (N=259;259;255;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" lower_limit="50.4" upper_limit="66.6"/>
                    <measurement group_id="O2" value="59.5" lower_limit="51.2" upper_limit="69.2"/>
                    <measurement group_id="O3" value="59.6" lower_limit="50.9" upper_limit="69.7"/>
                    <measurement group_id="O4" value="68.0" lower_limit="59.2" upper_limit="78.2"/>
                    <measurement group_id="O5" value="51.6" lower_limit="44.8" upper_limit="59.6"/>
                    <measurement group_id="O6" value="54.3" lower_limit="46.5" upper_limit="63.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia at Day 21 (N=259;259;255;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236.4" lower_limit="212.6" upper_limit="262.9"/>
                    <measurement group_id="O2" value="213.8" lower_limit="189.7" upper_limit="241.0"/>
                    <measurement group_id="O3" value="193.2" lower_limit="170.0" upper_limit="219.5"/>
                    <measurement group_id="O4" value="253.6" lower_limit="227.8" upper_limit="282.2"/>
                    <measurement group_id="O5" value="201.9" lower_limit="180.0" upper_limit="226.6"/>
                    <measurement group_id="O6" value="180.5" lower_limit="158.5" upper_limit="205.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroconverted for HI Antibodies Against Each of the Three Vaccine Strains for the Two Season Formulations</title>
        <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/New Caledonia (for all groups receiving vaccine formulations for the Northern Hemisphere [NH] 2006/2007 influenza season) or A/Solomon Islands (for all groups receiving vaccine formulations for the NH 2007/2008 influenza season), A/Wisconsin and B/Malaysia antigens.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK576389A- 2006/2007 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O2">
            <title>GSK576389A - 2006/2007 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 2006/2007 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
          </group>
          <group group_id="O4">
            <title>GSK576389A - 2007/2008 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O5">
            <title>GSK576389A - 2007/2008 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix 2007/2008 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroconverted for HI Antibodies Against Each of the Three Vaccine Strains for the Two Season Formulations</title>
          <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/New Caledonia (for all groups receiving vaccine formulations for the Northern Hemisphere [NH] 2006/2007 influenza season) or A/Solomon Islands (for all groups receiving vaccine formulations for the NH 2007/2008 influenza season), A/Wisconsin and B/Malaysia antigens.</description>
          <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="255"/>
                <count group_id="O4" value="258"/>
                <count group_id="O5" value="263"/>
                <count group_id="O6" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia strain (N=259;259;255;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                    <measurement group_id="O5" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                    <measurement group_id="O6" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands strain (N=0;0;0;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O2" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O3" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O4" value="177"/>
                    <measurement group_id="O5" value="192"/>
                    <measurement group_id="O6" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin strain (N=259;259;255;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="188"/>
                    <measurement group_id="O3" value="128"/>
                    <measurement group_id="O4" value="171"/>
                    <measurement group_id="O5" value="173"/>
                    <measurement group_id="O6" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia strain (N=259;259;255;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="108"/>
                    <measurement group_id="O5" value="111"/>
                    <measurement group_id="O6" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Seroconversion Factors</title>
        <description>Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/New Caledonia (for all groups receiving vaccine formulations for the Northern Hemisphere [NH] 2006/2007 influenza season) or A/Solomon Islands (for all groups receiving vaccine formulations for the NH 2007/2008 influenza season), A/Wisconsin and B/Malaysia antigens.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK576389A- 2006/2007 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O2">
            <title>GSK576389A - 2006/2007 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 2006/2007 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
          </group>
          <group group_id="O4">
            <title>GSK576389A - 2007/2008 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O5">
            <title>GSK576389A - 2007/2008 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix 2007/2008 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody Seroconversion Factors</title>
          <description>Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/New Caledonia (for all groups receiving vaccine formulations for the Northern Hemisphere [NH] 2006/2007 influenza season) or A/Solomon Islands (for all groups receiving vaccine formulations for the NH 2007/2008 influenza season), A/Wisconsin and B/Malaysia antigens.</description>
          <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity were available.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="255"/>
                <count group_id="O4" value="258"/>
                <count group_id="O5" value="263"/>
                <count group_id="O6" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia strain (N=259;259;255;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="3.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.5" lower_limit="3.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="3.3" lower_limit="2.8" upper_limit="3.8"/>
                    <measurement group_id="O4" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                    <measurement group_id="O5" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                    <measurement group_id="O6" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands strain (N=0;0;0;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O2" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O3" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O4" value="8.7" lower_limit="7.5" upper_limit="10.2"/>
                    <measurement group_id="O5" value="9.9" lower_limit="8.5" upper_limit="11.5"/>
                    <measurement group_id="O6" value="7.2" lower_limit="6.1" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin strain (N=259;259;255;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="6.7" upper_limit="9.4"/>
                    <measurement group_id="O2" value="7.8" lower_limit="6.6" upper_limit="9.2"/>
                    <measurement group_id="O3" value="5.2" lower_limit="4.3" upper_limit="6.3"/>
                    <measurement group_id="O4" value="7.0" lower_limit="6.0" upper_limit="8.3"/>
                    <measurement group_id="O5" value="7.0" lower_limit="5.9" upper_limit="8.3"/>
                    <measurement group_id="O6" value="4.2" lower_limit="3.5" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia strain (N=259;259;255;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="3.5" upper_limit="4.7"/>
                    <measurement group_id="O2" value="3.6" lower_limit="3.1" upper_limit="4.2"/>
                    <measurement group_id="O3" value="3.2" lower_limit="2.8" upper_limit="3.8"/>
                    <measurement group_id="O4" value="3.7" lower_limit="3.2" upper_limit="4.3"/>
                    <measurement group_id="O5" value="3.9" lower_limit="3.4" upper_limit="4.5"/>
                    <measurement group_id="O6" value="3.3" lower_limit="2.8" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroprotected for HI Antibodies Against Each of the Three Vaccine Strains for the Two Season Formulations</title>
        <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included A/New Caledonia (for all groups receiving vaccine formulations for the Northern Hemisphere [NH] 2006/2007 influenza season) or A/Solomon Islands (for all groups receiving vaccine formulations for the NH 2007/2008 influenza season), A/Wisconsin and B/Malaysia antigens.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK576389A- 2006/2007 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O2">
            <title>GSK576389A - 2006/2007 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 2006/2007 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
          </group>
          <group group_id="O4">
            <title>GSK576389A - 2007/2008 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O5">
            <title>GSK576389A - 2007/2008 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix 2007/2008 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroprotected for HI Antibodies Against Each of the Three Vaccine Strains for the Two Season Formulations</title>
          <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included A/New Caledonia (for all groups receiving vaccine formulations for the Northern Hemisphere [NH] 2006/2007 influenza season) or A/Solomon Islands (for all groups receiving vaccine formulations for the NH 2007/2008 influenza season), A/Wisconsin and B/Malaysia antigens.</description>
          <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="255"/>
                <count group_id="O4" value="258"/>
                <count group_id="O5" value="263"/>
                <count group_id="O6" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia at Day 0 (N=259;259;255;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="163"/>
                    <measurement group_id="O3" value="156"/>
                    <measurement group_id="O4" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                    <measurement group_id="O5" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                    <measurement group_id="O6" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia at Day 21 (N=259;259;255;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252"/>
                    <measurement group_id="O2" value="246"/>
                    <measurement group_id="O3" value="239"/>
                    <measurement group_id="O4" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                    <measurement group_id="O5" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                    <measurement group_id="O6" value="NA">Subjects in this group were not analysed for A/New Caledonia vaccine strain as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands at Day 0 (N=0;0;0;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O2" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O3" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands at Day 21 (N=0;0;0;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O2" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O3" value="NA">Subjects in this group were not analysed for A/Solomon Islands vaccine strain as per protocol.</measurement>
                    <measurement group_id="O4" value="202"/>
                    <measurement group_id="O5" value="215"/>
                    <measurement group_id="O6" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin at Day 0 (N=259;259;255;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="174"/>
                    <measurement group_id="O3" value="172"/>
                    <measurement group_id="O4" value="180"/>
                    <measurement group_id="O5" value="171"/>
                    <measurement group_id="O6" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin at Day 21 (N=259;259;255;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252"/>
                    <measurement group_id="O2" value="257"/>
                    <measurement group_id="O3" value="249"/>
                    <measurement group_id="O4" value="255"/>
                    <measurement group_id="O5" value="259"/>
                    <measurement group_id="O6" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia at Day 0 (N=259;259;255;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                    <measurement group_id="O2" value="188"/>
                    <measurement group_id="O3" value="185"/>
                    <measurement group_id="O4" value="200"/>
                    <measurement group_id="O5" value="184"/>
                    <measurement group_id="O6" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia at Day 21 (N=259;259;255;258;263;257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255"/>
                    <measurement group_id="O2" value="253"/>
                    <measurement group_id="O3" value="249"/>
                    <measurement group_id="O4" value="257"/>
                    <measurement group_id="O5" value="260"/>
                    <measurement group_id="O6" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</title>
        <description>Grade 3 ecchymosis, redness and swelling was greater than 100 millimeter (mm) i.e. &gt;100mm and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade. Any for ecchymosis, redness and swelling was &gt;20mm.</description>
        <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK576389A- 2006/2007 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O2">
            <title>GSK576389A - 2006/2007 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 2006/2007 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
          </group>
          <group group_id="O4">
            <title>GSK576389A - 2007/2008 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O5">
            <title>GSK576389A - 2007/2008 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix 2007/2008 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</title>
          <description>Grade 3 ecchymosis, redness and swelling was greater than 100 millimeter (mm) i.e. &gt;100mm and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade. Any for ecchymosis, redness and swelling was &gt;20mm.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="263"/>
                <count group_id="O5" value="268"/>
                <count group_id="O6" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="146"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="148"/>
                    <measurement group_id="O5" value="144"/>
                    <measurement group_id="O6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="131"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="108"/>
                    <measurement group_id="O5" value="120"/>
                    <measurement group_id="O6" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="53"/>
                    <measurement group_id="O5" value="49"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Solicited Local AEs</title>
        <description>Duration was defined as number of days with any grade of local symptoms.</description>
        <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK576389A- 2006/2007 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O2">
            <title>GSK576389A - 2006/2007 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 2006/2007 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
          </group>
          <group group_id="O4">
            <title>GSK576389A - 2007/2008 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O5">
            <title>GSK576389A - 2007/2008 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix 2007/2008 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited Local AEs</title>
          <description>Duration was defined as number of days with any grade of local symptoms.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="148"/>
                <count group_id="O5" value="144"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ecchymosis (N=4;4;5;7;7;10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="6.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="6.0" lower_limit="3.0" upper_limit="7.0"/>
                    <measurement group_id="O5" value="3.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O6" value="6.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (N=165;146;47;148;144;37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O4" value="3.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O5" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness (N=113;131;58;108;120;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O5" value="4.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (N=52;53;12;53;49;18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O5" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</title>
        <description>Any temperature was defined as oral temperature greater than or equal to 38.0 degree centigrade i.e ≥38.0°C, grade 3 temperature was oral temperature ≥39.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a general symptom that prevented normal activity. Related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK576389A- 2006/2007 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O2">
            <title>GSK576389A - 2006/2007 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 2006/2007 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
          </group>
          <group group_id="O4">
            <title>GSK576389A - 2007/2008 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O5">
            <title>GSK576389A - 2007/2008 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix 2007/2008 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</title>
          <description>Any temperature was defined as oral temperature greater than or equal to 38.0 degree centigrade i.e ≥38.0°C, grade 3 temperature was oral temperature ≥39.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a general symptom that prevented normal activity. Related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="264"/>
                <count group_id="O5" value="267"/>
                <count group_id="O6" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="83"/>
                    <measurement group_id="O5" value="82"/>
                    <measurement group_id="O6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="81"/>
                    <measurement group_id="O5" value="81"/>
                    <measurement group_id="O6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="62"/>
                    <measurement group_id="O5" value="58"/>
                    <measurement group_id="O6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="62"/>
                    <measurement group_id="O5" value="58"/>
                    <measurement group_id="O6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="75"/>
                    <measurement group_id="O5" value="77"/>
                    <measurement group_id="O6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="75"/>
                    <measurement group_id="O5" value="77"/>
                    <measurement group_id="O6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Solicited General AEs</title>
        <description>Duration was defined as number of days with any grade of general symptoms.</description>
        <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK576389A- 2006/2007 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O2">
            <title>GSK576389A - 2006/2007 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 2006/2007 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
          </group>
          <group group_id="O4">
            <title>GSK576389A - 2007/2008 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O5">
            <title>GSK576389A - 2007/2008 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix 2007/2008 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited General AEs</title>
          <description>Duration was defined as number of days with any grade of general symptoms.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="82"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia (N=58;36;19;39;30;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O6" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=89;90;39;83;82;33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=76;67;26;62;58;27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=85;63;25;75;77;29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (N=22;25;14;26;18;10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O6" value="1.5" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering (N=46;25;6;45;25;6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O6" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature (N=4;4;1;7;9;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="3.0" upper_limit="3.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O6" value="NA">Information on duration of fever was missing from these subject’s symptom sheets</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.</description>
        <time_frame>During a 21-day follow-up period (Day 0-20) after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK576389A- 2006/2007 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O2">
            <title>GSK576389A - 2006/2007 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 2006/2007 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
          </group>
          <group group_id="O4">
            <title>GSK576389A - 2007/2008 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O5">
            <title>GSK576389A - 2007/2008 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix 2007/2008 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="266"/>
                <count group_id="O3" value="264"/>
                <count group_id="O4" value="264"/>
                <count group_id="O5" value="268"/>
                <count group_id="O6" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="53"/>
                    <measurement group_id="O6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Medically Significant Conditions (MSCs)</title>
        <description>MSCs were defined as an AEs with a medically-attended visit (MAE) i.e. prompting emergency room (ER) visits, hospitalizations or physician visits and that were not routine visits for physical examination or vaccination. Any MSC was defined as at least one MSC experienced. Grade 3 was a MSC that prevented normal activities and related was defined as a MSC assessed by the investigator to be causally related to the study vaccination.</description>
        <time_frame>During a 21-day follow-up period (Day 0-20) after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK576389A- 2006/2007 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O2">
            <title>GSK576389A - 2006/2007 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 2006/2007 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
          </group>
          <group group_id="O4">
            <title>GSK576389A - 2007/2008 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O5">
            <title>GSK576389A - 2007/2008 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix 2007/2008 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Medically Significant Conditions (MSCs)</title>
          <description>MSCs were defined as an AEs with a medically-attended visit (MAE) i.e. prompting emergency room (ER) visits, hospitalizations or physician visits and that were not routine visits for physical examination or vaccination. Any MSC was defined as at least one MSC experienced. Grade 3 was a MSC that prevented normal activities and related was defined as a MSC assessed by the investigator to be causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="266"/>
                <count group_id="O3" value="264"/>
                <count group_id="O4" value="264"/>
                <count group_id="O5" value="268"/>
                <count group_id="O6" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any MSC(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 MSC(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related MSC(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During a 21-day follow-up period (Day 0-20) after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK576389A- 2006/2007 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O2">
            <title>GSK576389A - 2006/2007 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 2006/2007 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
          </group>
          <group group_id="O4">
            <title>GSK576389A - 2007/2008 Season - 1 Container Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.</description>
          </group>
          <group group_id="O5">
            <title>GSK576389A - 2007/2008 Season - 2 Containers Group</title>
            <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix 2007/2008 Season Group</title>
            <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="266"/>
                <count group_id="O3" value="264"/>
                <count group_id="O4" value="264"/>
                <count group_id="O5" value="268"/>
                <count group_id="O6" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE(S)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were assessed from day 0 to day 20. Systematically assessed frequent adverse events (AEs) and non-systematically assesed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.</time_frame>
      <desc>For the systematically assessed other (non-serious) adverse events, the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.</desc>
      <group_list>
        <group group_id="E1">
          <title>GSK576389A- 2006/2007 Season - 1 Container Group</title>
          <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.</description>
        </group>
        <group group_id="E2">
          <title>GSK576389A - 2006/2007 Season - 2 Containers Group</title>
          <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.</description>
        </group>
        <group group_id="E3">
          <title>Fluarix 2006/2007 Season Group</title>
          <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.</description>
        </group>
        <group group_id="E4">
          <title>GSK576389A - 2007/2008 Season - 1 Container Group</title>
          <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.</description>
        </group>
        <group group_id="E5">
          <title>GSK576389A - 2007/2008 Season - 2 Containers Group</title>
          <description>Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.</description>
        </group>
        <group group_id="E6">
          <title>Fluarix 2007/2008 Season Group</title>
          <description>Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="264"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="264"/>
                <counts group_id="E4" subjects_affected="148" subjects_at_risk="264"/>
                <counts group_id="E5" subjects_affected="144" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="51" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="265"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="263"/>
                <counts group_id="E4" subjects_affected="148" subjects_at_risk="263"/>
                <counts group_id="E5" subjects_affected="144" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="265"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="263"/>
                <counts group_id="E4" subjects_affected="108" subjects_at_risk="263"/>
                <counts group_id="E5" subjects_affected="120" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="51" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="265"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="263"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="263"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="265"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="263"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="264"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="267"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="265"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="263"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="264"/>
                <counts group_id="E5" subjects_affected="82" subjects_at_risk="267"/>
                <counts group_id="E6" subjects_affected="33" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="265"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="263"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="264"/>
                <counts group_id="E5" subjects_affected="58" subjects_at_risk="267"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="265"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="263"/>
                <counts group_id="E4" subjects_affected="75" subjects_at_risk="264"/>
                <counts group_id="E5" subjects_affected="77" subjects_at_risk="267"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="265"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="263"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="264"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="267"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="265"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="263"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="264"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="267"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="264"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="264"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

